Cercar
01/07/2026
Unraveling the spatial landscape of dystrophinopathies: a transcriptomic approach to Becker and Duchenne muscular dystrophies
Heezen, LG, Mao, QR, Nicolau, S, Rausell, CN, van der Weerd, J, Kueckelhaus, J, Nath, RG, Manera, JD, Kan, HE, Niks, EH, van Putten, M, Aartsma-Rus, A, Flanigan, KM, Mahfouz, A, Spitali, P. Unraveling the spatial landscape of dystrophinopathies: a transcriptomic approach to Becker and Duchenne muscular dystrophies. JOURNAL OF PATHOLOGY. 2026; 269(3)DOI:10.1002/path.70067. PMID:42067897. IF:5.200(Q1/1D).
01/07/2026
Visual mapping of muscle MRI fatty replacement patterns in genetic myopathies using dimensionality reduction
Pizarro-Galleguillos, B, Verdú-Diaz, J, Gómez-Andrés, D, Tobar, F, Montalba, C, Andia, M, Diaz-Manera, J, Jara, JD, Bevilacqua, JA. Visual mapping of muscle MRI fatty replacement patterns in genetic myopathies using dimensionality reduction. NEUROMUSCULAR DISORDERS. 2026; 64DOI:10.1016/j.nmd.2026.106464. PMID:42263369. IF:2.800(Q2/5D).
01/07/2026
Prognostic Determinants of Presentation and Outcome in Anti-IgLON5 Disease
Sabater, L, Guasp, M, García, RR, Rondán, LN, Querol, L, Martín-Aguilar, L, Llarch, P, Balasa, M, Lladó, A, Painous, C, Compta, Y, Serafim, AB, Montini, A, Iranzo, A, Cano, JS, Dalmau, JO, Graus, F, Gaig, C. Prognostic Determinants of Presentation and Outcome in Anti-IgLON5 Disease. Neurology-Neuroimmunology & Neuroinflammation. 2026; 13(4)DOI:10.1212/NXI.0000000000200600. PMID:42241645. IF:7.500(Q1/1D).
01/07/2026
Sensory neuronopathy secondary to gene therapy with AT845 for Pompe disease
Pena-Guzman, L, Bolano-Díaz, C, Lleixà, C, Querol, L, Trainor, C, Suetterlin, K, Straub, V, Díaz-Manera, J. Sensory neuronopathy secondary to gene therapy with AT845 for Pompe disease. NEUROMUSCULAR DISORDERS. 2026; 64DOI:10.1016/j.nmd.2026.106441. PMID:42142433. IF:2.800(Q2/5D).
01/07/2026
Rates and risk factors for major adverse cardiovascular and cerebrovascular events after stroke due to intracerebral hemorrhage: Systematic review and study-level meta-analysis
Putri, VP, Samarasekera, N, Moullaali, TJ, Jampana, S, Aked, J, Åsberg, S, Schulman, S, Tsivgoulis, G, Pikilidou, M, Tsai, HH, Tsai, LK, Myint, PK, Pana, TA, Cordonnier, C, Casolla, B, Gaist, D, Pezzini, A, Camps-Renom, P, Klijn, CJM, Romoli, M, Tveiten, A, Liu, M, Xu, MM, Wu, B, Werring, D, Nash, PS, Banerjee, G, Li, LX, Salman, RAS. Rates and risk factors for major adverse cardiovascular and cerebrovascular events after stroke due to intracerebral hemorrhage: Systematic review and study-level meta-analysis. International Journal of Stroke. 2026; 21(6)DOI:10.1177/17474930261416692. PMID:41605872. IF:8.700(Q1/1D).
01/07/2026
Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody-drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology
Majem, M, Mata, KM, Ibarguren, AM, Poves, MZ, Requena, C, Aparisi, FDA, Carrera, C, Cordellat, AB, Freites-Martinez, A, Sanmartin, O. Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody-drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology. Clinical & Translational Oncology. 2026; 28(7)DOI:10.1007/s12094-025-04209-0. PMID:41604110. IF:2.500(Q3/6D).